Here are the 10-K annual reports from Lakeside Holding Limited (LSH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LSH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LSH filings page.
Lakeside Holding (LSH) filed its annual report, highlighting a shift to a two-segment model and a challenging year. Total revenue was $17.8 million, down 2.9% year over year, as cross-border freight solutions fell 17.9% amid U.S. trade policy changes and softer demand. The company added a new line in December 2024, generating $2.8 million from pharmaceutical distribution.
Gross profit was $2.9 million (16.2% margin) versus $3.7 million (20.3%) last year, reflecting margin compression in freight (8.8% vs. 20.3%). Pharma posted a 56.1% gross margin, aided by supplier discounts as a new customer. Operating costs rose sharply—selling expenses increased with launch marketing, and G&A climbed 79.1%—driving a net loss of $5.25 million versus a $0.23 million loss a year ago. Interest expense increased 271.5%.
Liquidity at year-end included $5.0 million in cash, a current ratio of 1.06:1, positive working capital of $0.6 million, and $2.8 million in stockholders’ equity. Shares outstanding were 17,427,559 as of October 10, 2025. Management cites tariff uncertainty and de minimis changes as headwinds while scaling the pharma segment.